Knight Therapeutics (KHTRF) Gets a Buy Rating from Bloom Burton


In a report issued on June 29, David Martin from Bloom Burton maintained a Buy rating on Knight Therapeutics (KHTRF), with a price target of C$8.00. The company’s shares closed last Thursday at $5.35.

According to TipRanks.com, Martin is a 5-star analyst with an average return of 28.8% and a 53.2% success rate. Martin covers the Healthcare sector, focusing on stocks such as Aurinia Pharmaceuticals, ESSA Pharma, and CRH Medical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Knight Therapeutics with a $6.51 average price target, representing a 21.7% upside. In a report issued on June 26, Mackie Research also maintained a Buy rating on the stock with a C$8.90 price target.

See today’s analyst top recommended stocks >>

Based on Knight Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $45.84 million and GAAP net loss of $1.71 million. In comparison, last year the company earned revenue of $2.96 million and had a net profit of $5.19 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Knight Therapeutics Inc engages in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. It offers commercialized Rx and over-the-counter products, which includes Impavido, Movantik, ATryn, and AzaSite. The company was founded by Jonathan Ross Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts